TNFRSF10A and neoplasm: Animal models of xenogenic tumors treated with TRAIL-transduced MSCs provided evidence on the effectiveness of this cell-based approach in relation to the expression of DR4/DR5 by the target tumors [16, 33, 34, 39], although several concerns regard the defective specificity since the engineered MSCs also deliver TRAIL to both tumor and normal cells, and therefore normal tissues including liver and kidney are recurrently damaged following the systemic injections of these cells [27].